A rapid and specific approach for direct measurement of donepezil concentration in human plasma by LC-MS/MS employing solid-phase extraction

Biomedical Chromatography

Volumn 23, Issue 2, 2009, Pages 141-151

  Shah, Hiten J ^a,b,c   Kundlik, Mohan L ^a   Pandya, Ankit ^a   Prajapati, Shivkumar ^a   Subbaiah, Gunta ^a   Patel, Chhagan N ^b   Patel, Desharath M ^b   Suhagiya, Bhanu N ^c  

^a Torrent Research Centre   (India)

^b Shri Sarvajanik Pharmacy College   (India)

^c L M COLLEGE OF PHARMACY   (India)

Author keywords

Donepezil; Human plasma; LC MS MS; Multiple reaction monitoring

Indexed keywords

EXTRACTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHASE SEPARATION; PLASMA (HUMAN);

DIRECT MEASUREMENT; DONEPEZIL; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; MEASUREMENTS OF; MULTIPLE REACTION MONITORING; SIMPLE LIQUIDS; SOLID-PHASE EXTRACTION;

POSITIVE IONS;

DONEPEZIL; ESCITALOPRAM; FORMIC ACID; METHANOL; WATER;

ARTICLE; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; HUMAN; LIQUID CHROMATOGRAPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 65349126008     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1095     Document Type: Article

References (21)

1. Apostolou C, Dotsikas Y, Kousoulos C and Loukas YL. Quantitative determination of donepezil in human plasma by liquid chromatography/ tandem mass spectrometry employing an automated liquid-liquid extraction based on 96-well format plates Application to a bioequivalence study. Journal of Chromatography B 2007; 848: 239-244.
2. Bartus RT, Dean RL, Beer B and Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-417.
3. FDA. Guidance for Industry: Bioavailability Studies for Orally Administered Drug-Products-General Considerations. US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER): Washington, DC, 2000.
4. FDA. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research, Centre for Veterinary Medicine: Rockville, MD, May 2001.
5. Haginaka J and Scyama C. Determination of enantiomers of 1-benzyl-4- [(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride(E2020), a centrally acting acetylcholine esterase inhibitor, in plasma by liquid chromatography with fluorometric detection. Journal of Chromatography 1992; 577: 95-102.
6. Hao XY, Ding L, Li LM, Bian XJ and Zhang SQ. Bioequivalence of donepezil capsule and tablet in human. Yao Xue Xue Bao 2003; 38: 392-394.
7. Lee JW, Rogers SL, Friedhoff LT, Stiles MR and Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4- [(5,6-dimethoxy-1-indanon)-2-yl] methylpiperidine HCl (E2020) in human plasma. Pharmaceutical Research 1992; 9: S350.
8. Lu Y, Wen H, Li W, Chi Y and Zhang Z. Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. Journal of Chromatographic Science 2004; 42: 234-237.
9. Mahasen AR, Heba HA, Bushra TA, Hassan YA and Kenichiro N. Stereoselective HPLC assay of donepezil enantiomers with UV detection and its application to pharmacokinetics in rats. Journal of Chromatography B 2006; 830: 114-119.
10. Matsui K, Oda Y, Ohe H, Tanaka S and Asakawa N. Direct determination of E2020 enatiomers in plasma by liquid chromatography-mass spectrometry and column-switching techniques. Journal of Chromatography A 1995; 694: 209-218.
11. Matsui K, Mishima M, Nagai Y, Yuzuriha T and Yoshimura T. Absorption, distribution, metabolism, and extraction of donepezil (aricept) after a single oral administration to rat. Drug Metabolism and Disposition 1999a; 27: 1406-1414.
12. Matsui K, Oda Y, Nakata H and Yoshimura T. Simultaneous determination of donepezil (aricept®) enatiomers in human plasma by liquid chromatography-electrospray tandem mass spectrometry. Journal of Chromatography B 1999b; 729: 147-155.
13. Matsui K, Oda Y, Nakata H and Yoshimura T. Simultaneous determination of donepezil (aricept®) enantiomers in human plasma by liquid chromatography-electrospray tandem mass spectrometry. Journal of Chromatography B 2006; 729: 147-155.
14. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura, Yamazaki K and Morishita N. Pharmacokinetics of E202, a new compound for Alzheimer's disease, in healthy male volunteers. International Journal of Clinical Pharmacology Therapy and Toxicology 1993; 31: 223-229.
15. Moffat AC, Osselton MD and Widdop B, Clark's Analysis of Drugs and Poisons. Pharmaceutical Press, London 2004; 954.
16. 30 column. Journal of Pharmaceutical and Biomedical Analysis 2006; 41: 201-206.
17. Rho JP and Lipson LG. Focus on donepezil: a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Formulary 1997; 32: 677-678.
18. Rogers SL, Doody RS, Mohs RC and Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, doubleblind, placebo-controlled study. Archives of Internal Medicine 1998; 158: 1021-1031.
19. Xie Z, Loao Q, Xu X, Yao M, Wan J and Liu D. Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/ tandem mass spectrometry: application to a pharmacokinetic study. Rapid Communications in Mass Spectrometry 2006; 20: 3193-3198.
20. Yamanishi Y. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In: Nagatsu T, Fisher A, Yoshida M (eds). Basic, clinical and therapeutic aspect of Alzheimer's and Parkinson's disease. Plenum Press, London, 1990; 409-413.
21. Yasui-Furukori N, Furuya R, Takahata T and Tateishi T. Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. Journal of Chromatography B 2002; 768: 261-265.